|Awarded On||March 24, 2011|
|Title||Clinical Development of CaspaCIDe, a Cell Therapy Safety Switch|
|Program||Product Development Research|
|Award Mechanism||Company Commercialization|
|Institution/Organization||Bellicum Pharmaceuticals, Inc.|
|Principal Investigator/Program Director||Kevin Slawin|
|Cancer Sites||Leukemia, Lymphoma, Myeloma|
Many leukemia and lymphoma patients, including children and adults, are cured by a bone marrow transplant. However, cancer relapse, infection and GvHD are common in the months after a transplant. They cause suffering for the patient, are very difficult and expensive to manage, and are fatal for 30-50% of patients.
The problem is that harmful T cells in the transplant cannot be separated from essential, helpful T cells. These helpful T cells are better at eliminating residual cancer cells than the patient’s own T cells, they help the donor bone marrow cells become established, and they control infections that previously lay dormant. The harmful T cells cause GvHD by attacking the skin, the in...